MX2022004939A - Methods for treating patients having cfh mutations with recombinant cfh proteins. - Google Patents

Methods for treating patients having cfh mutations with recombinant cfh proteins.

Info

Publication number
MX2022004939A
MX2022004939A MX2022004939A MX2022004939A MX2022004939A MX 2022004939 A MX2022004939 A MX 2022004939A MX 2022004939 A MX2022004939 A MX 2022004939A MX 2022004939 A MX2022004939 A MX 2022004939A MX 2022004939 A MX2022004939 A MX 2022004939A
Authority
MX
Mexico
Prior art keywords
cfh
mutations
methods
proteins
recombinant
Prior art date
Application number
MX2022004939A
Other languages
Spanish (es)
Inventor
Lisa Huang
Scott Lauder
James Mclaughlin
Suresh Katti
Original Assignee
Gemini Therapeutics Sub Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemini Therapeutics Sub Inc filed Critical Gemini Therapeutics Sub Inc
Publication of MX2022004939A publication Critical patent/MX2022004939A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

The present disclosure provides methods for treating, preventing, or inhibiting diseases in patients having one or more mutations in complement factor H (CFH), complement component 3 (C3), and complement factor B (CFB). Also provided are combination therapies comprising a CFH protein and a VEGF antagonist for treating neovascularization-associated ocular diseases.
MX2022004939A 2019-10-23 2020-10-23 Methods for treating patients having cfh mutations with recombinant cfh proteins. MX2022004939A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962925071P 2019-10-23 2019-10-23
PCT/US2020/057155 WO2021081395A1 (en) 2019-10-23 2020-10-23 Methods for treating patients having cfh mutations with recombinant cfh proteins

Publications (1)

Publication Number Publication Date
MX2022004939A true MX2022004939A (en) 2022-08-10

Family

ID=75620320

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004939A MX2022004939A (en) 2019-10-23 2020-10-23 Methods for treating patients having cfh mutations with recombinant cfh proteins.

Country Status (7)

Country Link
US (1) US20220395557A1 (en)
EP (1) EP4048318A4 (en)
AU (1) AU2020371731A1 (en)
CA (1) CA3155404A1 (en)
IL (1) IL292247A (en)
MX (1) MX2022004939A (en)
WO (1) WO2021081395A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230088630A (en) * 2020-10-16 2023-06-20 자이로스코프 테라퓨틱스 리미티드 Nucleic acids encoding anti-VEGF entities and negative complement regulators and their use for the treatment of age-related macular degeneration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014035876A1 (en) * 2012-08-27 2014-03-06 William Marsh Rice University Heat-inactivated complement factor b compositions and methods
KR20140046781A (en) * 2012-10-11 2014-04-21 주식회사 메디진바이오 Composition for preventing or treating of choroidal neovascularization including complement factor h
FR3015484A1 (en) * 2013-12-20 2015-06-26 Lab Francais Du Fractionnement RECOMBINANT PROTEINS HAVING H-FACTOR ACTIVITY
US20190071477A1 (en) * 2015-12-31 2019-03-07 Quassia Biopharma Co., Ltd Recombinant complement Factor H-immunoglobulin fusion protein with complement regulatory activity, and preparation method therefor and use thereof
CN108934169A (en) * 2016-01-20 2018-12-04 维特里萨医疗公司 Composition and method for inhibiting factor D
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
CN111788311A (en) * 2017-10-20 2020-10-16 双子治疗公司 Compositions and methods for treating age-related macular degeneration
GB201800620D0 (en) * 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide

Also Published As

Publication number Publication date
IL292247A (en) 2022-06-01
EP4048318A1 (en) 2022-08-31
US20220395557A1 (en) 2022-12-15
CA3155404A1 (en) 2021-04-29
AU2020371731A1 (en) 2022-05-26
EP4048318A4 (en) 2023-11-22
WO2021081395A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
ZA202103912B (en) Irreversible inhibitors of menin-mll interaction
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
WO2018187227A8 (en) Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
PH12019500596A1 (en) Recombinant binding proteins and their use
WO2020072821A3 (en) Il-12 heterodimeric fc-fusion proteins
WO2009020559A3 (en) Agents that inhibit p-tefb interactions and methods of use thereof
NO20050827L (en) Use of interferon-B in the treatment of renal failure
MX2022009302A (en) Il-7rî± binding compounds.
MX2018013762A (en) Cd40l-fc fusion polypeptides and methods of use thereof.
WO2020061229A3 (en) Arc-based capsids and uses thereof
WO2015187998A3 (en) Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
MX2022003306A (en) Immunocytokine comprising heterodimeric protein complex based on il-15/il-15rî±.
MX2020014119A (en) Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a.
MX2021004188A (en) Disulfide bond stabilized polypeptide compositions and methods of use.
MX2022004939A (en) Methods for treating patients having cfh mutations with recombinant cfh proteins.
EP3805386A4 (en) Modified cas9 protein and use thereof
CO2022006367A2 (en) Gene therapy for Alzheimer's disease
MX2022011077A (en) Transglutaminase variants.
MX2017005522A (en) Novel treatment of cornea using laminin.
MX2021003606A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases.
EA202092530A1 (en) METHODS FOR FACILITATION OF OLD ASTENIA AND AGING
MX2022003945A (en) Method for treating hiv with cabotegravir and rilpivirine.
BR112019002355A2 (en) compositions and methods for stroke prevention in pediatric patients with sickle cell anemia
MX2021005386A (en) Peptide fragments for treatment of diabetes.
CR20220107A (en) Nkg2d fusion proteins and uses thereof